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Introduction: Epidermal growth factor receptor (EGFR) muta-
tions are found mostly in adenocarcinoma, and rarely in squamous 
cell carcinoma (SQC). Little is known about SQC harboring EGFR 
mutations.
Methods: Between April 2006 and October 2010, we investigated 
the incidence of EGFR activating mutations in SQC of the lung 
using the peptide nucleic acid-locked nucleic acid polymerase chain 
reaction clamp method. The efficacy of EGFR-tyrosine kinase inhib-
itors (TKIs) was retrospectively evaluated in patients with EGFR-
mutated SQC. Further pathologic analyses were performed using 
immunohistochemistry.
Results: Thirty-three of 249 patients with SQC (13.3%) had EGFR 
mutations, including exon 19 deletion (19 of 33 patients, 58%), 
L858R point mutation in exon 21 (12 of 33, 36%), and G719S 
point mutation in exon 18 (2 of 33, 6%). Twenty of these 33 patients 
received EGFR-TKI therapy, and five of these 20 responded to 
EGFR-TKIs with a response rate of 25.0% (95% confidence inter-
val [CI], 8.7%–49.1%). The patients’ median progression-free sur-
vival and median overall survival were 1.4 months (95% CI, 0.7–5.8 
months) and 14.6 months (95% CI, 2.9–undeterminable months), 
respectively. Approximately one third of the EGFR-mutated SQC 
patients achieved progression-free survival for longer than 6 months. 
Some of these patients had high carcinoembryonic antigen levels or 
a history of never smoking, or were positive for thyroid transcription 
factor-1.
Conclusions: Although EGFR-TKIs seem to be generally less effec-
tive in EGFR-mutated SQC than in EGFR-mutated adenocarcinoma, 
some EGFR-mutated SQC patients can obtain clinical benefit from 
EGFR-TKIs. To better identify these patients, not only EGFR muta-
tion status, but also clinical factors and pathologic findings should be 
taken into consideration.
Key Words: Squamous cell carcinoma, EGFR mutation, Epidermal 
growth factor–receptor tyrosine kinase inhibitor.
(J Thorac Oncol. 2013;8: 89–95)
The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) 
has been demonstrated in patients with EGFR-sensitive muta-
tions in non–small-cell lung cancers.1,2 In patients of east 
Asian ethnicity, EGFR mutations are found in adenocarci-
noma (ADC) relatively frequently (30%–40%), but rarely 
in other histologic subtypes.3 We occasionally detect EGFR 
mutations in squamous cell carcinoma (SQC) in our clinical 
practice. However, there is little data on the efficacy of EGFR-
TKIs for SQC harboring EGFR mutations.
The purposes of the present study were: first, to 
investigate the incidence of EGFR mutations in SQC patients 
in Japanese populations using a highly sensitive polymerase 
chain reaction (PCR) method and to identify the characteristics 
of EGFR-mutated SQC patients, and second, to evaluate the 
efficacy of EGFR-TKIs in these patients. In addition, we 
compared the efficacy of EGFR-TKIs between EGFR mutation-
positive and -negative SQC patients. We also performed 
immunohistochemistry (IHC) analyses to identify the pathologic 
features of histologic samples of EGFR-mutated SQC.
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PATIENTS AND METHODS
Patients and Specimens
Between April 2006 and October 2010, an EGFR muta-
tional analysis was performed in tumor specimens from 249 
patients with SQC at our institutes, regardless of whether or 
not the patients had undergone EGFR-TKI therapy. Tumor 
specimens were obtained by various methods: ultrasound or 
computed tomography–-guided needle biopsy, bronchoscopic 
transbronchial biopsy, cell blocks of malignant effusion, and 
surgical tissues. We isolated tumor DNA from various speci-
mens, and EGFR mutations were analyzed using the peptide 
nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp 
method, as reported by Nagai et al.4
We investigated the incidence of EGFR mutation in 
SQC of the lung. Patients with EGFR-mutated SQC were 
identified from records at our institutes, and their characteris-
tics (age, sex, smoking history, and types of EGFR mutation) 
were examined. Patients who reported never having smoked 
in their lifetime were defined as neversmokers, those who had 
smoked within 1 year of diagnosis were categorized as current 
smokers, and the rest were considered former smokers. This 
study was approved by the Institutional Review Board, and 
informed consent regarding the EGFR mutational analysis 
was obtained from all patients.
Evaluation of EGFR-TKI Efficacy
The initial doses of gefitinib and erlotinib were 250 mg/
day and 150 mg/day, respectively. Each drug was orally admin-
istered once a day until progressive disease (PD) or unaccept-
able toxicity was noted. Dose reduction or interruption was 
performed in the case of toxicity. Chest radiography was per-
formed every 1 to 4 weeks and a chest computed tomography 
scan was performed every 1 to 3 months. These procedures 
were also performed as needed to confirm response and dis-
ease progression. Tumor response was retrospectively evalu-
ated using the Response Evaluation Criteria in Solid Tumors.5 
Stable disease (SD) was defined as disease control maintained 
for at least 8 weeks. The duration of progression-free survival 
(PFS) was calculated from the date of initiation of EGFR-
TKIs to the date of disease progression. Overall survival (OS) 
time was determined from the date of initiation of EGFR-
TKIs to the date of death.
IHC Analyses and Pathologic Features
We retrospectively performed IHC analyses of 29 
available histologic samples from the 33 patients harboring 
EGFR mutations to examine their pathologic characteristics in 
greater detail. Representative formalin-fixed paraffin-embed-
ded tumor blocks were selected and used for the IHC. After 
deparaffinization of 3- to 4-μm-thick sections, heat-induced 
antigen retrieval was performed with an ethylenediaminetet-
raacetic acid solution (pH 8.0). The sections were treated with 
3% hydrogen peroxide to block endogenous peroxidase activ-
ity. The reaction of relevant antibodies was carried out follow-
ing the manufacturer’s instructions.
We adopted a multiplex IHC analysis with four kinds of 
antibody cocktail (ADC cocktail and SQC cocktail, Pathology 
Institute Corp., Toyama, Japan), consisting of the follow-
ing monoclonal antibodies: mouse for thyroid transcription 
factor 1(TTF-1; clone SPT24), mouse for napsin-A (clone 
TMU-Ad02), mouse for p63 (clone 4A4), and mouse for 
CK14 (clone LL002). TTF-1/napsin-A for the differentiation 
of ADC and p63/CK14 for SQC have been reported as effec-
tive IHC antibodies.6–11 In this multiplex IHC method, TTF-1 
labels ADCs’ nuclei, and napsin-A labels cytoplasm. SQC 
carcinomas could be differentiated from ADCs by the fol-
lowing staining patterns: nuclear staining with p63 and cyto-
plasmic staining with CK14. Expert pathologists (KN and YI) 
evaluated the immunoreactivities. We defined tumors exhibit-
ing a diffuse staining pattern or at least a mean positive area 
of 10% or more in the relevant cells as immunopositive (+); 
tumors exhibiting weak or 10% or lesser focal staining pat-
terns as slightly positive (±); and tumors whose staining was 
completely absent as negative (−). The efficacy of a similar 
method using the same four antibodies has been described.12 
We also pathologically reassessed these 29 histologic samples 
to examine tumor differentiation and SQC features such as 
keratinization.
STATISTICAL ANALYSIS
The response rate (RR) and disease-control rate were 
compared between the EGFR-mutation–positive and –nega-
tive patients using Fisher’s exact test. PFS and OS curves 
were estimated according to the Kaplan–Meier method. PFS 
and OS were compared between the EGFR-mutation–positive 
and –negative patients using the log-rank test. Statistical 
analysis was performed using JMP 7 (SAS Institute, Inc., 
Cary, NC).
RESULTS
Incidence of EGFR Mutations in SQC of  
the Lung
With the PNA-LNA PCR clamp method, EGFR mutations 
were detected in 33 of the 249 patients with SQC of the lung, 
making the incidence of EGFR mutations in these SQCs 13.3%.
Characteristics of EGFR-Mutated SQC Patients
The characteristics of the patients harboring EGFR 
mutations are shown in Table 1. Twelve of the 33 patients 
(36%) were women, and seven (21%) were neversmokers. 
Two (6%) patients had a point mutation in exon 18 (G719X), 
19 (58%) had a deletion mutation in exon 19, and 12 (36%) 
had a point mutation in exon 21 (L858R).
Efficacy of EGFR-TKIs
Between January 2000 and October 2010, 81 patients 
with SQC received gefitinib or erlotinib as their first TKI 
therapy (excluding readministration of EGFR-TKIs). All 
these patients had unresectable and advanced/metastatic 
disease. Of these 81 patients, 20 were EGFR-mutation 
positive, 33 were EGFR-mutation negative, and 28 were 
unknown. EGFR-TKIs were administered to 20 of the 33 SQC 
patients harboring EGFR mutations, and to the 33 EGFR-
mutation–negative patients. A comparison of characteristics 
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between the EGFR-mutation–positive and –negative patients 
is shown in Table 2. Most of the EGFR-mutation–positive 
patients received gefitinib, whereas most of the EGFR-
mutation–negative patients received erlotinib. Other patient 
characteristics, including previous and subsequent therapies, 
were not significantly different between the EGFR-mutation–
positive and –negative patients.
Among the EGFR-mutation–positive patients (n = 20), 
one complete response (CR), four partial response (PR), and 
six SD were confirmed, seven patients were judged as hav-
ing PD, and the responses of two patients were not evaluable. 
Among the EGFR-mutation–negative patients (n = 33), zero 
CR, three PR, 11 SD, 18 PD, and one not evaluable were 
confirmed. The RRs (EGFR-positive versus -negative) were 
25.0% (95% confidence interval [CI], 8.7%–49.1%) ver-
sus 9.1% (95% CI, 1.9%–24.3%), respectively (p = 0.1372). 
The disease-control rates were 50.0% (95% CI, 31.5%–
76.9%) versus 42.4% (95% CI, 25.5%–60.8%), respectively 
(p = 0.7765).
The median PFS values (EGFR-positive versus -nega-
tive) were 1.4 months (95% CI, 0.7–5.8 months) versus 1.8 
months (95% CI, 1.0–2.4 months) (p = 0.1734) (Fig. 1). 
Approximately one third of the 20 EGFR-mutation–positive 
patients obtained a PFS longer than 6 months. The median 
OS values were 14.6 months (95% CI, 2.9–undeterminable 
months) versus 11.0 months (95% CI, 5.7–15.7 months) for 
the EGFR-mutation–positive and –negative patients, respec-
tively (p = 0.5472) (Fig. 2).
IHC Results and Pathologic Features
The results of the IHC analyses performed on the 29 
available histologic samples from 33 EGFR-mutated SQC 
patients are shown in Table 3. Clinical, mutational, and 
pathologic characteristics are also shown. Thirteen (45%) 
poorly, nine (31%) moderately, and seven (24%) well-dif-
ferentiated SQCs were diagnosed. Elevated carcinoembry-
onic antigen (CEA) levels (> 10 ng/ml) were confirmed in 
TABLE 1.  Characteristics of Patients with EGFR-Mutated 
Squamous Cell Carcinoma (n = 33)
Patient Characteristics No. of patients %
Age (yr)
 Median (range) 70 (49–83)
Sex
 Male 21 64
 Female 12 36
Smoking history
 Never  7 21
 Former 13 39
 Current 13 39
Types of EGFR mutation
 Exon 18 (G719X)  2  6
 Exon 19 (deletion) 19 58
 Exon 21 (L858R) 12 36
EGFR, epidermal growth factor receptor.
TABLE 2.  Comparison of EGFR-Mutation–Positive and 
–Negative Squamous Cell Carcinoma Patients
Characteristics EGFR Mutation
-Positive (n = 20)
EGFR Mutation
-Negative (n = 33)
Age (yr)
 Median (range) 68 (56–82) 67 (44–84)
Prior regimens
 Median (range) 2 (0–4) 3 (2–6)
Sex
 Male 14 (70%) 26 (79%)
 Female 6 (30%) 7 (21%)
Smoking history
 Never 4 (20%) 3 (9%)
 Former 6 (30%) 10 (30%)
 Current 10 (50%) 20 (61%)
PS (ECOG)
 0, 1 18 (90%) 28 (85%)
 2, 3, 4 2 (10%) 5 (15%)
Types of EGFR-TKI
 Gefitinib 18 (90%) 1 (3%)
 Erlotinib 2 (10%) 32 (97%)
Front-line therapy
 Platinum doublets 14 (70%) 23 (70%)
 Nonplatinum doublets 1 (5%) 3 (9%)
 Monotherapy 2 (10%) 7 (21%)
 Gefitinib 3 (15%) 0 (0%)
Subsequent therapies
 Cytotoxic therapies 16 (80%) 29 (88%)
 None 4 (20%) 4 (12%)
PS, performance status; ECOG, Eastern Cooperative Oncology Group; EGFR, 
epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. 
FIGURE 1.  Progression-free survival of EGFR-positive versus 
-negative squamous cell carcinoma patients. EGFR-mutation 
positive (n = 20): 1.4 months; EGFR-mutation negative (n = 33): 
1.8 months. p = 0.1734
EGFR mutation-positive (n=20): 1.4 months
EGFR mutation-negative (n=33): 1.8 months
p = 0.1734
EGFR, epidermal growth factor receptor.
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nine patients. Keratinization was found in 21 (72%) of the 
29 samples. With respect to IHC results for SQC, p63 and 
CK14 were positive in 25 (86%) and 12 (41%) patients, 
respectively, whereas IHC results for ADC, TTF-1, and nap-
sin-A were positive in six (21%) and four (14%) patients, 
respectively.
DISCUSSION
Recent reports document the incidence of EGFR muta-
tions in SQC of the lung as extremely rare: 2.6%3 (6 of 230; 
includes adenosquamous and large-cell carcinoma), 0% (0 of 
454),13 and 0% (0 of 102).14 The incidence in the present study 
was 13.3% (33 of 249), much higher than those of the cited 
studies. We used the PNA-LNA PCR clamp method, which 
is a highly sensitive PCR technique, so that minor EGFR-
mutated populations in an SQC tumor might be detected. 
Similarly, Tanaka et al.15 demonstrated that the incidence of 
EGFR mutations in non-ADC including SQC was 12.1% (8 
of 66) using the same method. Moreover, using an even more 
TABLE 3.  Clinical, Mutational, and Pathologic Factors, and Immunohistochemistry Findings
No.
Age(yr) 
Sex
CEA  
ng/ml
Smoking 
Status
EGFR 
Mutation
Response 
to TKIs
Differentiation/
Keratinization p63/CK14
TTF-1/
Napsin-A
1 64F 270 Never Del-19 CR Poor/− − /− +/−
2 56M 1.5 Current Del-19 PR Poor/− − /− − /−
3 68F 14.3 Former Del-19 SD Moderate/+ +/− − /−
4 78F 2.6 Former Del-19 / Moderate/+ +/+ − /−
5 62M 3.8 Current Del-19 PD Moderate/+ +/− +/−
6 74M 3.1 Former L858R / Moderate/+ +/+ − /−
7 78M 2.2 Former L858R / Well/+ + / + − /−
8 56M 7.2 Former Del-19 PR Poor/+ +/− − /−
9 59M 51.9 Former L858R SD Moderate/+ +/− ±/+
10 73M 4.1 Current Del-19 / Well/+ + / + − /−
11 60M 16.5 Former Del-19 / Well/+ +/− − /−
12 56M 4.3 Former L858R / Moderate/+ +/− − /−
13 81F 7.3 Never G719A / Poor/+ +/− − /−
14 74M 19.3 Former G719S / Moderate/+ +/+ +/+
15 68M 8.3 Current Del-19 SD Poor/+ + / ± − /−
16 67F 0.9 Never Del-19 SD Well/+ +/+ − /−
17 49M 1.1 Current L858R / Moderate/+ +/− − /−
18 73M 3.5 Former L858R SD Poor/− +/− − /−
19 75F 499 Never L858R PR Poor/− +/− +/+
20 60M 4.8 Current Del-19 NE Well/+ +/+ − /−
21 77M 6.1 Current L858R PD Poor/− +/+ − /−
22 75M 4.1 Current Del-19 PD Well/+ −/+ − /−
23 83M / Current L858R / Poor/− +/− − /−
24 76M 4.8 Former Del-19 NE Moderate/+ +/− − /−
25 54F / Current L858R / Poor/+ +/+ − /−
26 67F 22.1 Current L858R PD Poor/− +/− − /−
27 68M / Current Del-19 / Poor/− − /− − /−
28 82F 266 Never L858R SD Well/+ +/+ +/+
29 74M 14.0 Former Del-19 PD Poor/+ +/− − /−
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CK, cytokeratin; TTF-1, thyroid transcription factor-1; Del-19, deletion mutation 
in exon 19; L858R, point mutation in exon 21; G719X; point mutation in exon 18; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable.
FIGURE 2.  Overall survival curves of EGFR-positive and 
-negative squamous cell carcinoma patients. EGFR mutation-
negative (n = 33): 11.0 months; EGFR mutation-positive | 
(n = 20): 14.6 months. p = 0.5472.
p = 0.5472
EGFR mutation-positive (n=20): 14.6 months
EGFR mutation-negative (n=33): 11.0 months
EGFR, epidermal growth factor receptor.
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sensitive technique (denaturing high-performance liquid chro-
matography) that can detect EGFR mutations even in plasma 
DNA samples, Bai et al.16 demonstrated that the incidence of 
EGFR mutations in non-ADC including SQC was 20.3% (12 
of 59). These higher incidences were all reported from Asia, 
and previous reports from western countries reveal that EGFR 
mutations are rarely found in white SQC populations. Our 
present findings and the results of the Tanaka et al. and Bai 
et al. studies reveal a higher incidence of EGFR mutations in 
SQC among Asian populations compared with that in white 
populations, after using highly sensitive methods. The muta-
tion rate of SQC may vary by methodology and ethnicity, as 
does that of ADC.
The characteristics of the EGFR-mutated SQC patients 
in the present study show that more women (36%) and nev-
ersmokers (22%) were included than are typical among SQC 
patients. The lack of smoking history is unusual for typical 
SQC (1%–3% in other studies).17–19 This implies that EGFR-
mutated SQC may have a different nature from typical SQC. 
The proportions of each EGFR mutation in our study (G719X, 
6%; del-19, 58%; and L858R, 36%) were mostly consistent 
with those previously reported.20 If uncommon mutations 
are frequently detected, we need to address the possibility 
of experimental artifacts. Marchetti et al.21 pointed out that 
experimental artifacts because of postmortem deamination 
are possible in cases of uncommon EGFR mutations, espe-
cially if the samples are extracted from paraffin-embedded 
small samples. Our data included no uncommon mutations. 
To the best of our knowledge, there are no reports that com-
mon mutations such as del-19, L858R, and G719X arise as 
artifacts. We therefore believe that it is unlikely that our data 
include experimental artifacts.
In the present study, the RR and median PFS of the 
EGFR-mutated SQC patients were 25.0% and 1.4 months, 
respectively. Shukuya et al.22 also conducted a pooled analysis 
of 27 published EGFR-mutated SQCs, and they found that the 
RR and median PFS were 30% and 3.1 months, respectively. 
These results are clearly inferior to pivotal data for EGFR-
mutated ADC, for which, in general, the RR and median PFS 
have been reported to be 70% to 80% and 9 to 11 months, 
respectively.23–27 EGFR-TKIs seem to be less effective in 
EGFR-mutated SQC than in EGFR-mutated ADC.
However, Figure 1 shows that approximately one third 
of the EGFR mutation-positive patients obtained a PFS of 
longer than 6 months. In addition, Figure 2 shows that after 
approximately 1 year, survival curves separate between the 
EGFR mutation-positive and -negative patients, a result which 
may be because of the efficacy of EGFR-TKIs. We think it 
important to be able to identify from all EGFR-mutated 
SQC patients those who can obtain clinical benefit from 
EGFR-TKIs.
Among the EGFR-mutated SQC patients treated with 
EGFR-TKIs, four (80%) of the five TTF-1–positive patients 
obtained clinical benefit (CR, PR, or SD). Patients with 
TTF-1–positive tumors were likely to have ADC propensity. 
Meanwhile, only one (9%) of the 11 p63/CK14-positive and 
TTF-1/napsin-A-negative tumors responded to EGFR-TKIs. 
Tumors with these IHC patterns were more compatible with 
pure SQC lineages. Further, three (75%) of the four patients 
with both p63/CK14- and TTF-1/napsin-A–positive tumors 
obtained clinical benefit. These double-positive IHC patterns 
suggest mixed components of ADC and SQC. Patient 2 was 
the only patient with both p63/CK14- and TTF-1/napsin-
A–negative tumors, and he responded to gefitinib. The TTF-1/
p63 double-negative profile is interpreted as indeterminate 
but favoring ADC.28 Considering these results, patients with 
tumors containing greater ADC lineages can obtain more clin-
ical benefit from EGFR-TKIs. Conversely, patients with pure 
SQC tumor lineages may obtain little clinical benefit.
Of the group of patients who obtained clinical benefit 
from EGFR-TKIs, some were neversmokers and/or exhibited 
high CEA levels. Patient 1 was a nonsmoking woman with 
markedly elevated CEA. Her initial diagnosis was poorly dif-
ferentiated SQC. It is well known that poorly differentiated 
ADC and SQC can seem indistinguishable by light micros-
copy.29 In fact, the IHC pattern of Patient 1 suggested ADC 
lineages. We consider her tumor to be poorly differentiated 
ADC, morphologically mimicking SQC. Patients 9, 19, and 28 
were light smokers, and their CEA levels were also elevated. 
In Patient 9, apparent keratinization was confirmed at the ini-
tial pathologic examination. However, after staining with TTF-
1, glandular patterns emerged in the retrospective pathologic 
reassessment. IHC showing a p63/CK14 and TTF-1/napsin-A 
double-positive pattern suggests mixed components of ADC 
and SQC. Although the definition of AD-SQC requires that 
both glandular and squamous components represent at least 
10% of the tumor mass,30 the double-positive IHC pattern rep-
resents the AD-SQC lineage. The incidence of EGFR mutations 
in AD-SQC is known to be similar to that in ADC, and their 
responsiveness to EGFR-TKIs has also been reported.31–36 We 
speculate that some EGFR-mutated SQCs (especially those that 
obtain clinical benefit from EGFR-TKIs) are indeed an incom-
plete sampling of AD-SQC and poorly differentiated ADC 
morphologically mimicking SQC. To identify these patients, it 
is important to examine not only IHC results, but also clinical 
characteristics such as smoking status and CEA level.
Approximately one half of the EGFR-mutated SQC 
patients failed to benefit from EGFR-TKIs in the present 
study. The absence of EGFR mutations has been demonstrated 
in pure SQC,28 and we also consider EGFR-mutated SQC not 
to be pure SQC. In our speculation, a highly sensitive PCR 
technique can detect EGFR-mutated, malignant (probably 
ADC) cells as a minor population in a tumor, but SQC cells 
as a major population are wild-type EGFR. Thus, EGFR-TKIs 
for EGFR-mutated SQC are generally less effective than in 
EGFR-mutated ADC. A minor glandular component may not 
be represented in microscopically scrutinized tissue.
Notably, similar situations have been reported in small-
cell lung cancer (SCLC).37–41 These reports suggest that EGFR 
mutations are rare, but can be found in SCLC, and that EGFR-
TKIs are generally less effective in EGFR-mutated SCLC than 
in EGFR-mutated ADC, even though some EGFR-mutated 
SCLC patients obtained clinical benefit from EGFR-TKIs. 
Most of these patients were neversmokers, and had a mixed 
ADC histology. Regardless of SQC and SCLC histologies, the 
sensitivity of EGFR-TKIs in patients with non-ADC harbor-
ing EGFR mutations may depend on the proportion of EGFR-
mutated ADC components in the whole tumor.
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Some of our EGFR-mutated SQC patients were diag-
nosed by small specimens that might have included an 
incomplete sampling of AD-SQC. Roggli et al.42 addressed 
histologic heterogeneity in a comprehensive study of 100 lung 
cancer cases in which two (5%) of 39 ADC patients showed an 
SQC component, and an ADC component was found in four 
(15%) of 27 SQC cases (15%). In these cases, the morpho-
logic features of SQC or ADC differentiation were focal or not 
distinguishable. Pathology experts have noted the difficulty 
and complexity of pathologic diagnosis, especially based on 
small biopsies.29
The diagnostic limitations of small biopsies and intra-
tumoral heterogeneity make definitive diagnoses difficult. 
Clinicians should understand the limitations of pathologic 
diagnosis based on small biopsies, and they need to cooper-
ate with pathologists to better reach a diagnosis for individual 
patients. It has recently become more important to distinguish 
SQC from ADC to decrease the incidence of life-threatening 
hemorrhage with bevacizumab,43 to obtain better efficacy with 
pemetrexed,44 and to select populations harboring the more 
frequent EGFR mutations.3
In conclusion, the incidence of EGFR mutations in SQC 
of the lung was not low in the Japanese populations tested 
with the present highly sensitive PCR method. Although the 
efficacy of EGFR-TKIs for EGFR-mutated SQC is generally 
inferior to that for EGFR-mutated ADC, some EGFR-mutated 
SQC patients can obtain clinical benefit from EGFR-TKIs. In 
the Japanese population (which has a high incidence of EGFR 
mutations), EGFR mutational analysis is recommended even 
for SQC to identify the patients who might benefit, and other 
factors should also be taken into consideration, including 
clinical factors such as smoking status and pathologic findings 
such as differentiation and IHC results, and tumor markers, 
such as CEA level. Considering the utility and complexity 
of pathologic diagnoses, interaction between clinicians and 
pathologists has become more important. Given that the 
present data are retrospective and that we had a small sample 
size, RR and PFS are very soft endpoints, and the RR and PFS 
were assessed by the investigators. In addition, the interval for 
the restaging imaging was highly variable, and this represents a 
bias for PFS assessment. Further investigations are warranted 
to validate the efficacy of EGFR-TKIs for EGFR-mutated 
SQC patients. We are therefore conducting a phase II trial to 
evaluate the efficacy of gefitinib for EGFR-mutated non-ADC 
NSCLC.
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